Insider trading

Period: 120 months Stock: NVCR Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

343 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

343 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

343 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

343 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
343 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
343 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

343 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
4 Jun 2026
Leonard Frank X Chief Executive Officer
Sold at will
$614.63K 34,273 at 17.93
6.9%
Not planned
5 Mar 2026
Paravasthu Mukund Chief Operating Officer
Sold at will
$595.67K 43,246 at 13.77
37.3%
Not planned
3 Mar 2026
DOYLE WILLIAM F Executive Chairman
Sold at will 2×
$932.88K 71,887 at 12.98
18.0%
Not planned
27 Feb 2026
Leonard Frank X Chief Executive Officer
Sold at will
$133.00K 9,734 at 13.66
2.8%
Not planned
27 Feb 2026
Weinberg Uri Chf Medical and Innovation Ofr
Sold at will
$103.26K 7,461 at 13.84
3.4%
Not planned
5 Sep 2025
Cordova Ashley Chief Executive Officer
Bought
$996.86K 81,550 at 12.22
22.9%
First buy on file
29 Jul 2025
Brackmann Christoph Chief Financial Officer
Bought 3×
$231.80K 20,000 at 11.59
16.5%
First buy on file
2 Jun 2025
Leonard Frank X EVP, Pres., Novocure Oncology
Sold on a plan 3×
$528.41K 30,196 at 17.50
15.2%
Planned (10b5-1)
27 Feb 2025
Leonard Frank X EVP, Pres., Novocure Oncology
Sold at will 2×
$245.61K 12,266 at 20.02
7.6%
Not planned
27 Feb 2025
Cordova Ashley Chief Executive Officer
Sold at will 2×
$223.32K 11,153 at 20.02
5.1%
Not planned
7 Mar 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated 2×
$625.21K 8,318 at 75.16
13.3%
3 Mar 2023
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold, plan not stated 3×
$1.95M 25,635 at 76.16
10.9%
3 Mar 2023
Shah Pritesh Chief Growth Officer
Sold, plan not stated 3×
$1.63M 21,421 at 76.16
14.6%
3 Mar 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated 3×
$562.82K 7,350 at 76.57
10.5%
3 Mar 2023
Cordova Ashley Chief Financial Officer
Sold, plan not stated 2×
$419.26K 5,505 at 76.16
5.2%
2 Mar 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated 3×
$373.11K 4,951 at 75.36
7.8%
1 Mar 2023
Cordova Ashley Chief Financial Officer
Sold, plan not stated
$167.84K 2,198 at 76.36
2.2%
1 Mar 2023
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold, plan not stated
$165.25K 2,164 at 76.36
1.2%
1 Mar 2023
Shah Pritesh Chief Growth Officer
Sold, plan not stated
$146.84K 1,923 at 76.36
1.9%
1 Mar 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$128.59K 1,684 at 76.36
2.6%
5 Jan 2023
Danziger Asaf Chief Executive Officer
Sold, plan not stated 10×
$23.11M 212,500 at 108.74
94.0%
Sold half or more
5 Jan 2023
Leonard Frank X President, CNS Cancers US
Sold, plan not stated 9×
$4.43M 39,507 at 112.25
46.1%
5 Jan 2023
Weinberg Uri Chief Science Officer
Sold, plan not stated 4×
$945.76K 8,143 at 116.14
15.8%
13 Oct 2022
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$513.37K 6,754 at 76.01
13.4%
6 Oct 2022
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$569.83K 6,754 at 84.37
11.8%
29 Sep 2022
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$522.42K 6,754 at 77.35
10.6%
22 Sep 2022
Leonard Frank X President, CNS Cancers US
Sold, plan not stated
$520.06K 6,754 at 77.00
9.6%
15 Sep 2022
Leonard Frank X Chief Development Officer
Sold, plan not stated 2×
$1.09M 12,271 at 88.52
14.8%
9 Sep 2022
Leonard Frank X Chief Development Officer
Sold, plan not stated
$163.94K 1,863 at 88.00
2.2%
6 Sep 2022
Leonard Frank X Chief Development Officer
Sold, plan not stated
$108.74K 1,384 at 78.57
1.6%
1 Sep 2022
Leonard Frank X Chief Development Officer
Sold, plan not stated 12×
$1.10M 14,212 at 77.43
13.9%
3 Aug 2022
Benaim Ely Chief Medical Officer
Sold, plan not stated 2×
$439.33K 5,959 at 73.73
17.2%
11 May 2022
Benaim Ely Chief Medical Officer
Sold, plan not stated
$130.77K 2,135 at 61.25
5.8%
10 May 2022
Benaim Ely Chief Medical Officer
Sold, plan not stated
$134.88K 2,070 at 65.16
5.3%
9 Mar 2022
Shah Pritesh Chief Commercial Officer
Sold, plan not stated
$261.20K 3,669 at 71.19
4.2%
8 Mar 2022
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold, plan not stated
$204.90K 2,923 at 70.10
1.7%
8 Mar 2022
Shah Pritesh Chief Commercial Officer
Sold, plan not stated
$173.92K 2,481 at 70.10
2.9%
8 Mar 2022
DOYLE WILLIAM F Executive Chairman
Sold, plan not stated
$167.19K 2,385 at 70.10
0.4%
8 Mar 2022
Longsworth Todd Christopher General Counsel
Sold, plan not stated
$163.96K 2,339 at 70.10
3.6%
7 Mar 2022
Shah Pritesh Chief Commercial Officer
Sold, plan not stated
$368.20K 5,294 at 69.55
5.9%
4 Mar 2022
Shah Pritesh Chief Commercial Officer
Sold, plan not stated 2×
$327.79K 4,546 at 72.11
4.8%
4 Mar 2022
GROENHUYSEN WILHELMUS CM Chief Operating Officer
Sold, plan not stated
$180.88K 2,569 at 70.41
1.5%
4 Mar 2022
Longsworth Todd Christopher General Counsel
Sold, plan not stated
$138.91K 1,973 at 70.41
3.0%
4 Mar 2022
Benaim Ely Chief Medical Officer
Sold, plan not stated
$106.31K 1,510 at 70.41
3.4%
3 Jan 2022
Burke William Patrick Chief Human Resources Officer
Sold, plan not stated 3×
$300.26K 3,951 at 76.00
8.8%
26 Nov 2021
Danziger Asaf Chief Executive Officer
Bought 3×
$509.54K 4,974 at 102.44
59.9%
First buy on file
2 Sep 2021
Cordova Ashley Chief Financial Officer
Sold, plan not stated
$114.46K 828 at 138.23
1.9%
12 Aug 2021
Cordova Ashley Chief Financial Officer
Sold, plan not stated 5×
$3.75M 26,624 at 140.94
36.7%
5 Aug 2021
LEUNG GABRIEL Director
Sold, plan not stated
$152.50K 1,000 at 152.50
1.4%
4 Aug 2021
Shah Pritesh Chief Commercial Officer
Sold, plan not stated
$306.79K 2,063 at 148.71
2.7%
Showing 1–50 of 343. Page 1 of 7 Older →